NEW YORK (TheStreet) -- RATINGS CHANGES Avis Budget was upgraded to buy at TheStreet Ratings. Bristol-Myers was downgraded at Morgan Stanley to equal-weight from overweight. Stock is now discounting higher odds of success for new drug in development, creating unbalanced risk-reward dynamic, Morgan Stanley said. Must Read: 10 Stocks Carl Icahn Loves in 2014 Broadcom was upgraded at Goldman Sachs to buy from neutral. Product cycles in 2015/2016 should drive EPS upside, Goldman said. Twelve-month price target was raised to $48 from $40. Jabil Circuit was downgraded at Goldman Sachs to neutral from buy. Stock is approaching its 12-month price target of $22, and customer concentration poses additional risk, Goldman said. Vale was downgraded to sell at TheStreet Ratings. Must Read: Two Ways to Play Energy Despite Dismal Oil Price Forecasts Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes", which is available only to Real Money subscribers. To find out how to become a subscriber, please click here. Follow TheStreet on Twitter and become a fan on Facebook.
Click to view a price quote on BMY. Click to research the Drugs industry.
from Latest TSC Headlines http://ift.tt/1EyClrZ
No comments:
Post a Comment